The Demonstrated Safety of AFSTYLA

AFSTYLA safety was evaluated in the largest hemophilia A pivotal clinical trial program to date (258 participants)

ZERO INHIBITORS

Zero inhibitors were observed in the AFSTYLA clinical trial

14 of 258 participants reported a side effect

One person withdrew due to a side effect (allergic reaction).

Side effects by patient percentage

0.4%

Tingling (paresthesia)

Rash

Redness (erythema)

Itching (pruritus)

Fever (pyrexia)

Injection-site pain

Chills

Feeling hot

0.8%

Dizziness

1.6%

Allergic reaction

Get your free AFSTYLA Discovery Kit

Sign up today!

Sign-up now
You are now leaving the current website.

Do you want to continue?

No Yes